Table 1.
Jumonji domain-containing protein 3 demethylase regulation in liver, ovarian, and gastric cancers a.
| Types of Cancer | Up/Down Regulation | How? | Oncogene/ Tumor Suppressor |
References |
|---|---|---|---|---|
| Liver | Upregulated | + EMT + Migration + Invasion via slug demethylation |
Oncogene | [99] |
| Downregulated by miR-941 in hepato carcinoma cell lines | − EMT − Invasion − Migration − Proliferation |
Tumor Suppressor | [100] | |
| Ovarian | - | + Cell death + Self-renewal + Tumor initiation |
Oncogene | [101] |
| Upregulated | + EMT + Migration + Invasion + Proliferation + Metastatic Capacities via TGF-β1 expression |
Oncogene | [102] | |
| Upregulated in drug resistant ovarian cancer cells, positively correlated with HER2 expression | + HER2 expression | Oncogene | [103] | |
| Gastric | Upregulated | − Survival + Proliferation |
Oncogene | [104] |
| - | + p15/p16 when associated with Long noncoding RNAs (ARHGAP27P1) | Tumor suppressor |
[105] | |
| Glioblastoma | Upregulated | + Tumor growth + Proliferation − Apoptosis + Migration + Invasion + EMT (SNAI1 and fibronectin and N-cadherins by regulating CXCL12) |
Oncogene | [39,40,41,42,43] |
| + P53 − Neurosphere formation − Proliferation |
Tumor suppressor |
[46,47,49] | ||
| Medulloblastoma | Upregulated | + Proliferation (+ shh signaling) | Oncogene | [51] |
| Downregulated | + DNA repair (+ topoIIβ) |
Tumor suppressor |
[52] | |
| Neuroblastoma | - | + Differentiation (− MYCN) + Apoptosis (p53, PUMA) + Cell death (+ reticulo-endoplasmic stress) |
Tumor suppressor |
[53,54] |
| Prostate cancer | Upregulated (Differential expression according to AR status and aggressiveness) |
+ Proliferation + Senescence |
Oncogene | [61,66] |
| − Proliferation + DNA repair (+ MGMT) |
Tumor suppressor |
[55,57,59,62,65] | ||
| T-ALL | Upregulated | + NOTCH1 target genes + Tumor growth + AP-1 |
Oncogene | [67,68,69,70] |
| AML | - | + Differentiation + Cell cycle arrest + Cell death (+ C/EBPβ and RIPK3) |
Tumor suppressor |
[71,72] |
| Upregulated | + Proliferation + Disease progression + HOX cAMP/PKA |
Oncogene | [73,74,75] | |
| HV | Upregulated | JMJD3 activated by LMP1 + NOTCH2NL |
Oncogene | [76] |
| DLBCL | Upregulated | + Survival (BCR, BCL6, IRF4-NF-kB, BCL2)− Apoptosis (XIAP, MCL1) | Oncogene | [77,78,79] |
| ALCL | - | + p16INK4a/Rb pathway | Tumor suppressor |
[80] |
| - | + Proliferation (+ EpCam) + Tumor growth +Migration (NOTCH1/JMJD3 → +) |
Oncogene | [85,86] | |
| Colorectal cancer | Downregulated | JMJD3 activated by Vitamin D active metabolite − EMT (− SNAI1, − ZEB1, + cell adhesion genes) − Proliferation + Apoptosis + P15INK4B + Survival (+CXCL9, CXCL10) |
Tumor suppressor |
[81,82,83,84] |
| Breast cancer | - | − Survival (+ BCL2) + Proliferation + Pluripotency (Nanog, Sox, Oct4) + Tumor growth + EMT (JMJD3 activated by TGFβ → + SNAI1) |
Oncogene | [88,90,91,93] |
| - | − Pluripotency (− Oct4)− Stem-like properties − EMT (+DICER → − miR-200) |
Tumor suppressor |
[89,92,94] | |
| Lung cancer | Upregulated | + Cell cycle (− p21) + EMT (Migration) + Metastasis − Survival |
Oncogene | [95,96,97,98] |
a EMT: Epithelial-mesenchymal transition; CXCL12: C-X-C motif chemokine 12; topoIIβ: Topoisomerase iiβ; SNAI1: Snail homolog 1; ZEB1: Zinc finger E-box-binding homeobox 1; Topoisomerase iiβ; MGMT: O—methylguanine-DNA methyltransferase; NOTCH1: Notch receptor 1; CREB: cAMP response element-binding protein; PKA: Protein kinase A; LMP1: Latent membrane protein-1; NOTCH2NL: Notch homolog 2 N-terminal-like; BCR: B-cell receptor; BCL6: B-cell lymphoma 6 protein; IRF4: Regulatory factor 4 interferon; BCL2: B-cell lymphoma 2 protein; XIAP: X-linked inhibitor of apoptosis; PUMA: p53 upregulated modulator of apoptosis; MCL1: Myeloid cell leukemia 1; EpCam: Epithelial cell adhesion molecule; JMJD3: Jumonji Domain-Containing Protein 3 demethylase.